

Ref. No: 183130721  
From: Commercial  
Date: 13/07/21  
Subject: New biologic medications

## REQUEST

I am analysing the usage of new biologic medications for the treatment of dermatological and rheumatological conditions. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients were treated in June 2021 (or latest available month) by the dermatology department with the following drugs:

- Baricitinib (Olmiant)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)

Q2. How many patients were treated in June 2021 (or latest available month) by the rheumatology department with the following drugs:

- Baricitinib (Olmiant)
- Filgotinib (Jyseleca)
- Ixekizumab (Taltz)
- Secukinumab (Cosentyx)
- Upadacitinib (Rinvoq)

## RESPONSE

### Pharmacy Response:

Number of patients dispensed with selected drug between 1<sup>st</sup> June 2021 to 1<sup>st</sup> July 2021:

Q1: Dermatology:

Baricitinib (Olmiant)	0
Dupilumab (Dupixent)	20
Ixekizumab (Taltz)	0
Risankizumab (Skyrizi)	*
Guselkumab (Tremfya)	*
Secukinumab (Cosentyx)	*

Q2: Rheumatology:

Baricitinib (Olmiant)	24
Filgotinib (Jyseleca)	0
Ixekizumab (Taltz)	0
Secukinumab (Cosentyx)	17
Upadacitinib (Rinvoq)	0

Please note \* has been added when the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.